{"id":70042,"date":"2026-04-13T12:37:44","date_gmt":"2026-04-13T07:07:44","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=70042"},"modified":"2026-04-13T12:37:45","modified_gmt":"2026-04-13T07:07:45","slug":"blogs-divi-labs-target-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/","title":{"rendered":"Divi&#8217;s Laboratories Share Price Target 2026: Analyst Consensus, Bull Case &amp; Bear Case"},"content":{"rendered":"<p>Divi&#8217;s Laboratories (Pharma \/ CDMO) is trading at Rs 4,200 as of April 2026, with a 52-week range from Rs 3,900 to Rs 6,200 and a 1-year return of -32%. The analyst consensus 12-month Divi&#8217;s Laboratories share price target stands at Rs 5,000-5,800 \u2014 implying meaningful potential movement from current levels.<\/p><p>Whether you are a long-term holder reassessing your position or a new investor evaluating entry levels, understanding where analysts see Divi&#8217;s Laboratories heading over the next 12-24 months requires looking beyond the CMP. This article covers the key catalysts and risks, technical levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term Divi&#8217;s Laboratories share price targets.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2014 Get Free Investment Predictions on Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Divis_Laboratories_Key_Data_%E2%80%94_CMP_Valuation_Fundamentals\" title=\"Divi&#8217;s Laboratories Key Data \u2014 CMP, Valuation, Fundamentals\">Divi&#8217;s Laboratories Key Data \u2014 CMP, Valuation, Fundamentals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Divis_Laboratories_Share_Price_Targets_%E2%80%94_Short-Term_12-Month_Long-Term\" title=\"Divi&#8217;s Laboratories Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term\">Divi&#8217;s Laboratories Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Bull_Case_%E2%80%94_What_Has_to_Go_Right_for_Divis_Laboratories\" title=\"Bull Case \u2014 What Has to Go Right for Divi&#8217;s Laboratories\">Bull Case \u2014 What Has to Go Right for Divi&#8217;s Laboratories<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#1_CDMO_business_ramping\" title=\"1. CDMO business ramping\">1. CDMO business ramping<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#2_China1_strategy_benefiting_Divis\" title=\"2. China+1 strategy benefiting Divi&#8217;s\">2. China+1 strategy benefiting Divi&#8217;s<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#3_Nutraceuticals_API_business_expanding_into_US_branded_nutrition_market\" title=\"3. Nutraceuticals API business expanding into US branded nutrition market\">3. Nutraceuticals API business expanding into US branded nutrition market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#4_Revenue_and_PAT_recovery_expected_in_FY27_as_Chinese_API_pricing_pressure_normalises\" title=\"4. Revenue and PAT recovery expected in FY27 as Chinese API pricing pressure normalises\">4. Revenue and PAT recovery expected in FY27 as Chinese API pricing pressure normalises<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#5_Promoter_familys_technical_background_in_complex_synthesis_providing_genuine_IP_advantage\" title=\"5. Promoter family&#8217;s technical background in complex synthesis providing genuine IP advantage\">5. Promoter family&#8217;s technical background in complex synthesis providing genuine IP advantage<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Bear_Case_%E2%80%94_Key_Risks_to_the_Divis_Laboratories_Share_Price_Target\" title=\"Bear Case \u2014 Key Risks to the Divi&#8217;s Laboratories Share Price Target\">Bear Case \u2014 Key Risks to the Divi&#8217;s Laboratories Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Risk_1_API_pricing_remaining_depressed_if_Chinese_overcapacity_persists_longer_than_expected\" title=\"Risk 1: API pricing remaining depressed if Chinese overcapacity persists longer than expected\">Risk 1: API pricing remaining depressed if Chinese overcapacity persists longer than expected<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Risk_2_CDMO_programme_delays_pushing_revenue_contribution_to_FY29-30_instead_of_FY28\" title=\"Risk 2: CDMO programme delays pushing revenue contribution to FY29-30 instead of FY28\">Risk 2: CDMO programme delays pushing revenue contribution to FY29-30 instead of FY28<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Institutional_Sentiment_and_Technical_Analysis\" title=\"Institutional Sentiment and Technical Analysis\">Institutional Sentiment and Technical Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Conclusion_%E2%80%94_Our_View_on_name_Share_Price_Target\" title=\"Conclusion \u2014 Our View on ${name} Share Price Target\">Conclusion \u2014 Our View on ${name} Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Q1_What_is_Divis_Laboratories_share_price_target_2026\" title=\"Q1. What is Divi&#8217;s Laboratories share price target 2026?\">Q1. What is Divi&#8217;s Laboratories share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Q2_Is_Divis_Laboratories_a_good_buy_now\" title=\"Q2. Is Divi&#8217;s Laboratories a good buy now?\">Q2. Is Divi&#8217;s Laboratories a good buy now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Q3_What_is_Divis_Laboratoriess_current_valuation\" title=\"Q3. What is Divi&#8217;s Laboratories&#8217;s current valuation?\">Q3. What is Divi&#8217;s Laboratories&#8217;s current valuation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Q4_What_are_the_key_risks_for_Divis_Laboratories\" title=\"Q4. What are the key risks for Divi&#8217;s Laboratories?\">Q4. What are the key risks for Divi&#8217;s Laboratories?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Q5_Where_can_I_track_Divis_Laboratories_share_price_live\" title=\"Q5. Where can I track Divi&#8217;s Laboratories share price live?\">Q5. Where can I track Divi&#8217;s Laboratories share price live?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/blogs-divi-labs-target-share-price-target-2026\/#Recent_Articles\" title=\"Recent Articles\">Recent Articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Divis_Laboratories_Key_Data_%E2%80%94_CMP_Valuation_Fundamentals\"><\/span><strong>Divi&#8217;s Laboratories Key Data \u2014 CMP, Valuation, Fundamentals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 4,200<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 6,200<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 3,900<\/td><\/tr><tr><td>1-Year Return<\/td><td>-32%<\/td><\/tr><tr><td>Trailing P\/E<\/td><td>52x<\/td><\/tr><tr><td>Price-to-Book<\/td><td>7.8x<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 1.1L Cr<\/td><\/tr><tr><td>Sector<\/td><td>Pharma \/ CDMO<\/td><\/tr><tr><td>Promoter Holding<\/td><td>51.9%<\/td><\/tr><tr><td>FII Holding<\/td><td>22.6%<\/td><\/tr><tr><td>DII Holding<\/td><td>18.4%<\/td><\/tr><\/tbody><\/table><\/figure><p>Track live <strong>Divi&#8217;s Laboratories<\/strong> fundamentals and analyst ratings on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Divis_Laboratories_Share_Price_Targets_%E2%80%94_Short-Term_12-Month_Long-Term\"><\/span><strong>Divi&#8217;s Laboratories Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Access premium analyst research on Univest<\/strong><\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Scenario<\/strong><\/td><td><strong>Target<\/strong><\/td><td><strong>Basis<\/strong><\/td><\/tr><tr><td>Short-Term (3-6M)<\/td><td>Rs 5,000<\/td><td>Technical support; near-term catalyst<\/td><\/tr><tr><td>12-Month Consensus<\/td><td>Rs 5,000-5,800<\/td><td>Analyst consensus based on current fundamentals<\/td><\/tr><tr><td>Bull Case (FY28)<\/td><td>Rs 7,500<\/td><td>Full execution of growth catalysts below<\/td><\/tr><tr><td>Bear Case<\/td><td>Rs 3,200<\/td><td>Materialisation of key risks below<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bull_Case_%E2%80%94_What_Has_to_Go_Right_for_Divis_Laboratories\"><\/span><strong>Bull Case \u2014 What Has to Go Right for Divi&#8217;s Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_CDMO_business_ramping\"><\/span><strong>1. CDMO business ramping<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>first large-scale Phase 3 CDMO batches at Vizag facility creating future NDA-commercial pipeline<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_China1_strategy_benefiting_Divis\"><\/span><strong>2. China+1 strategy benefiting Divi&#8217;s<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>US pharma companies actively qualifying Indian API sources<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Nutraceuticals_API_business_expanding_into_US_branded_nutrition_market\"><\/span><strong>3. Nutraceuticals API business expanding into US branded nutrition market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nutraceuticals API business expanding into US branded nutrition market<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Revenue_and_PAT_recovery_expected_in_FY27_as_Chinese_API_pricing_pressure_normalises\"><\/span><strong>4. Revenue and PAT recovery expected in FY27 as Chinese API pricing pressure normalises<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Revenue and PAT recovery expected in FY27 as Chinese API pricing pressure normalises<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Promoter_familys_technical_background_in_complex_synthesis_providing_genuine_IP_advantage\"><\/span><strong>5. Promoter family&#8217;s technical background in complex synthesis providing genuine IP advantage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Promoter family&#8217;s technical background in complex synthesis providing genuine IP advantage<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bear_Case_%E2%80%94_Key_Risks_to_the_Divis_Laboratories_Share_Price_Target\"><\/span><strong>Bear Case \u2014 Key Risks to the Divi&#8217;s Laboratories Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_1_API_pricing_remaining_depressed_if_Chinese_overcapacity_persists_longer_than_expected\"><\/span><strong>Risk 1: API pricing remaining depressed if Chinese overcapacity persists longer than expected<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>API pricing remaining depressed if Chinese overcapacity persists longer than expected<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_2_CDMO_programme_delays_pushing_revenue_contribution_to_FY29-30_instead_of_FY28\"><\/span><strong>Risk 2: CDMO programme delays pushing revenue contribution to FY29-30 instead of FY28<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>CDMO programme delays pushing revenue contribution to FY29-30 instead of FY28<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Institutional_Sentiment_and_Technical_Analysis\"><\/span><strong>Institutional Sentiment and Technical Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Divi&#8217;s Laboratories has 22.6% FII holding and 18.4% DII holding. High FII ownership of 22.6% means the stock is sensitive to global risk-off events \u2014 FII selling can be disproportionate to any specific negative news.<\/p><p>Technically, Divi&#8217;s Laboratories is trading at Rs 4,200 against a 52-week range of Rs 3,900 to Rs 6,200. The -32% 1-year return positions the stock in negative territory \u2014 creating both risk of further downside and opportunity for mean reversion. The 12-month analyst target of Rs 5,000-5,800 implies the stock is expected to recover meaningfully from current depressed levels.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for real-time research and analyst updates.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion_%E2%80%94_Our_View_on_name_Share_Price_Target\"><\/span><strong>Conclusion \u2014 Our View on ${name} Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Divi&#8217;s Labs at Rs 4,200 and 52x trailing P\/E on suppressed earnings looks expensive. But at 15-18x FY28 earnings (when CDMO ramp is expected to be meaningful), the stock is attractively priced. The China+1 API qualification opportunity and CDMO business represent multi-year growth drivers. 12-month target of Rs 5,000-5,800 requires FY27 earnings recovery evidence.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Subscribe to Univest Pro for SEBI-registered analyst recommendations \u2014 entry, target, stop-loss.<\/strong><\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q1_What_is_Divis_Laboratories_share_price_target_2026\"><\/span><strong>Q1. What is Divi&#8217;s Laboratories share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Divi&#8217;s Laboratories share price target for 2026 is Rs 5,000-5,800 based on analyst consensus. The bull case target is Rs 7,500 and the bear case is Rs 3,200. These are analyst estimates, not guaranteed returns.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q2_Is_Divis_Laboratories_a_good_buy_now\"><\/span><strong>Q2. Is Divi&#8217;s Laboratories a good buy now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Divi&#8217;s Laboratories is trading at Rs 4,200 against a 52-week range of Rs 3,900 to Rs 6,200. Analyst consensus target of Rs 5,000-5,800 implies upside from current levels. Consult a SEBI-registered financial advisor before investing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q3_What_is_Divis_Laboratoriess_current_valuation\"><\/span><strong>Q3. What is Divi&#8217;s Laboratories&#8217;s current valuation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Divi&#8217;s Laboratories trades at a trailing P\/E of 52x and price-to-book of 7.8x with a market capitalisation of Rs 1.1L Cr. The stock&#8217;s valuation relative to earnings growth determines the appropriate entry point.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q4_What_are_the_key_risks_for_Divis_Laboratories\"><\/span><strong>Q4. What are the key risks for Divi&#8217;s Laboratories?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Key risks for Divi&#8217;s Laboratories include the factors outlined in the Bear Case section of this article. API pricing remaining depressed if Chinese overcapacity persists longer than expected is the primary near-term risk to watch.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q5_Where_can_I_track_Divis_Laboratories_share_price_live\"><\/span><strong>Q5. Where can I track Divi&#8217;s Laboratories share price live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Track Divi&#8217;s Laboratories share price live, quarterly results, FII\/DII activity, and analyst ratings on the Univest Screener at univest.in\/screeners. Download the Univest iOS or Android App for daily research.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates and may change. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making any investment decisions.<\/p><p>For more stock research, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Articles\"><\/span>Recent Articles<span class=\"ez-toc-section-end\"><\/span><\/h2><p>&nbsp;<a href=\"https:\/\/univest.in\/blogs\/why-is-krbl-share-price-falling\"><strong>Why is KRBL Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-reliance-infrastructures-share-price-falling\"><strong>Why is Reliance Infrastructures Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-mahanagar-gas-share-price-falling\"><strong>Why is Mahanagar Gas Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-happiest-minds-share-price-falling\"><strong>Why is Happiest Minds Share Price Falling? Check Next Share Price Target<\/strong><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Divi&#8217;s Laboratories (Pharma \/ CDMO) is trading at Rs 4,200 as of April 2026, with a 52-week range from Rs 3,900 to Rs 6,200 and a 1-year return of -32%. The analyst consensus 12-month Divi&#8217;s Laboratories share price target stands at Rs 5,000-5,800 \u2014 implying meaningful potential movement from current levels. Whether you are a<\/p>\n","protected":false},"author":26,"featured_media":70046,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-70042","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"_edit_lock":["1776064126:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["78"],"rank_math_focus_keyword":["Divi's Laboratories"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_title":[" Divi's Laboratories Share Price Target 2026: Analyst Estimates, Bull &amp; Bear Case"],"rank_math_description":[" Divi's Laboratories share price target 2026 \u2014 analyst consensus Rs 5,000-5,800. CMP Rs 4,200, 12M target, bull case Rs 7,500, bear case Rs 3,200. Full analysis.\n"],"_thumbnail_id":["70046"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7871"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13123639\/divi-labs-target_.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=70042"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70042\/revisions"}],"predecessor-version":[{"id":70049,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70042\/revisions\/70049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/70046"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=70042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=70042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=70042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}